Cellectis S.A. (CLLS)
NASDAQ: CLLS
· Real-Time Price · USD
1.34
-0.03 (-1.96%)
At close: Jun 13, 2025, 3:57 PM
1.42
5.97%
After-hours: Jun 13, 2025, 05:48 PM EDT
-1.96% (1D)
| Bid | 1.32 |
| Market Cap | 141.1M |
| Revenue (ttm) | 41.51M |
| Net Income (ttm) | -36.76M |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | -2 |
| Forward PE | -1.29 |
| Analyst | Buy |
| Ask | 1.61 |
| Volume | 63,523 |
| Avg. Volume (20D) | 309,111 |
| Open | 1.39 |
| Previous Close | 1.37 |
| Day's Range | 1.33 - 1.43 |
| 52-Week Range | 1.10 - 2.43 |
| Beta | 3.20 |
About CLLS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLLS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts10 months ago
+12.2%
Cellectis shares are trading higher after the comp...
Unlock content with
Pro Subscription
10 months ago
+0.49%
Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.
